Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 15/20 | 0.46 |
| ▸ | KCNE1 | P15382 | 3/20 | 0.43 |
| ▸ | KCNQ1 | P51787 | 3/20 | 0.43 |
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3321626 | 1.00 | TRPV1 (0.46) | TRPV1KCNE1KCNQ1HTR2BCYP3A4 | |
| SCHEMBL3327193 | 0.89 | TRPV1 (0.44) | TRPV1KCNE1KCNQ1CYP3A4 | |
| SCHEMBL3327189 | 0.89 | TRPV1 (0.44) | TRPV1KCNE1KCNQ1CYP3A4 | |
| SCHEMBL3321457 | 0.84 | TRPV1 (0.42) | TRPV1KCNE1KCNQ1HTR2BCYP3A4 | |
| SCHEMBL3321453 | 0.84 | TRPV1 (0.42) | TRPV1KCNE1KCNQ1HTR2BCYP3A4 | |
| SCHEMBL15075093 | 0.82 | TRPV1 (0.46) | TRPV1KCNE1KCNQ1CYP3A4 | |
| SCHEMBL15086531 | 0.79 | TRPV1 (0.42) | TRPV1KCNE1KCNQ1CYP3A4 | |
| SCHEMBL3322619 | 0.78 | TRPV1 (0.41) | TRPV1KCNE1KCNQ1CYP3A4 | |
| SCHEMBL3322624 | 0.78 | TRPV1 (0.41) | TRPV1KCNE1KCNQ1CYP3A4 | |
| SCHEMBL6024931 | 0.78 | TRPV1 (0.41) | TRPV1KCNE1KCNQ1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609692-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-8604053-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2013-12-10 | — | — | US | disclosed |
| CN-102245587-A | Trpv1 antagonists | ABBOTT LAB | 2011-11-16 | — | — | CN | disclosed |
| CN-102186836-A | Trpv1 antagonists | ABBOTT LAB | 2011-09-14 | — | — | CN | disclosed |
| US-20100137360-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100120846-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-05-13 | — | — | US | disclosed |
| US-20090143423-A1 | SOLID DISPERSION PRODUCT CONTAINING N-ARYL UREA-BASED COMPOUND | ABBOTT GMBH & CO. KG (DE) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137360-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPV2 | TRPV1 1/4885KCNE1 258/4885KCNQ1 306/4885 |
| US-20100120846-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPV2 | TRPV1 1/4885KCNE1 266/4885KCNQ1 321/4885 |
| US-20090143423-A1 | SOLID DISPERSION PRODUCT CONTAINING N-ARYL UREA-BASED COMPOUND | U2SURP, UMPS, HNRNPUL1 | TRPV1 4781/4885KCNE1 3907/4885KCNQ1 3831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.